ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 503,27
-2,66%
Dow Jones
38 589,16
-0,15%
DAX
18 002,02
-1,43%
Brent Oil
82,275
0,00%
Bitcoin
66 144,18
-0,07%
Registration Strip Icon for alerts Inscrivez-vous pour des alertes en temps réel, un portefeuille personnalisé et des mouvements de marché.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Rigel Pharmaceuticals Inc (RIGL)

  7. Rigel Pharmaceuticals Inc (RIGL) Actualités

RIGL Rigel Pharmaceuticals Inc

0,9503
-0,0236 (-2,42%)
15 Juin 2024 - Fermé
Retardé de 15 minutes
Nom Action Symbole Action Marché Type
Rigel Pharmaceuticals Inc RIGL NASDAQ Action ordinaire
  Variation Action Variation Action% Cours Dernier Dernier échange
Upgrade Icon
-0,0236 -2,42% 0,9503 06:00:06
Ouverture Plus Bas Plus Haut Prix de clôture Clôture Veille
0,9686 0,9449 0,99 0,953 0,9739
plus d'informations sur les cotations »

Actualités Recentes

Date Heure Source Titre
14/6/202409:05PRNUSRigel Announces Five Presentations at the EHA2024 Hybrid..
03/6/202414:13PRNUSRigel Highlights New Data in Three Poster Presentations at..
30/5/202414:05PRNUSRigel to Present at the Jefferies Global Healthcare..
30/5/202401:21EDGAR2Form 4 - Statement of changes in beneficial ownership of..
30/5/202401:21EDGAR2Form 4 - Statement of changes in beneficial ownership of..
30/5/202401:20EDGAR2Form 4 - Statement of changes in beneficial ownership of..
30/5/202401:20EDGAR2Form 4 - Statement of changes in beneficial ownership of..
30/5/202401:20EDGAR2Form 4 - Statement of changes in beneficial ownership of..
30/5/202401:19EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/5/202422:06EDGAR2Form 8-K - Current report
23/5/202423:00PRNUSRigel Announces Presentations at the Upcoming 2024 ASCO..
07/5/202422:16EDGAR2Form 8-K - Current report
07/5/202422:01PRNUSRigel Reports First Quarter 2024 Financial Results and..
30/4/202414:05PRNUSRigel Announces Conference Call and Webcast to Report First..
10/4/202422:30PRNUSRigel Announces Inducement Grants under NASDAQ Listing Rule..
04/4/202414:05PRNUSRigel Announces Publication of Data on REZLIDHIA®..
12/3/202413:05PRNUSRigel Pharmaceuticals Announces Appointment of Lisa..
05/3/202422:10EDGAR2Form 8-K - Current report
05/3/202422:06EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
05/3/202422:01PRNUSRigel Reports Fourth Quarter and Full Year 2023 Financial..
02/3/202401:16EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/3/202401:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/3/202401:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/3/202401:14EDGAR2Form 4 - Statement of changes in beneficial ownership of..
27/2/202414:05PRNUSRigel Announces Conference Call and Webcast to Report Fourth..
22/2/202414:00EDGAR2Form 8-K - Current report
22/2/202413:50PRNUSRigel Pharmaceuticals Acquires U.S. Rights to GAVRETO®
14/2/202420:30EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
07/2/202402:18EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07/2/202402:18EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07/2/202402:18EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/2/202415:56EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
26/1/202403:17EDGAR2Form 4 - Statement of changes in beneficial ownership of..
26/1/202403:17EDGAR2Form 4 - Statement of changes in beneficial ownership of..
26/1/202403:17EDGAR2Form 4 - Statement of changes in beneficial ownership of..
26/1/202403:16EDGAR2Form 4 - Statement of changes in beneficial ownership of..
25/1/202419:48EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
08/1/202414:30EDGAR2Form 8-K - Current report
08/1/202414:05PRNUSRigel Pharmaceuticals Provides Business Update
05/1/202422:30PRNUSRigel Announces Inducement Grants under NASDAQ Listing Rule..
04/1/202414:05PRNUSRigel Announces Collaboration with CONNECT to Conduct a..
03/1/202414:05PRNUSRigel to Present at the 42nd Annual J.P. Morgan Healthcare..
08/12/202314:05PRNUSRigel Pharmaceuticals and MD Anderson Announce Strategic..
30/11/202312:04EDGAR2Form 8-K - Current report
07/11/202322:16EDGAR2Form 8-K - Current report
07/11/202322:05EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
07/11/202322:01PRNUSRigel Reports Third Quarter 2023 Financial Results and..
06/11/202314:05PRNUSRigel to Present at the Jefferies London Healthcare..
02/11/202314:27PRNUSRigel Announces Poster Presentations at the 65th American..
31/10/202313:05PRNUSRigel Announces Conference Call and Webcast to Report Third..

Dernières Valeurs Consultées

NASDAQ
RIGL
Rigel Pharmaceuticals
LSE
39VO
Res.mtg 17 A2bs
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés